Drugs / CBL-A1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06005441 | Nov 2023 → Oct 2024 | panniculitis | Caliway Biopharmaceuticals Co., Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-05 | Caliway Biopharmaceuticals Co., Ltd. | Results 康霈新藥最終二期CBL-514 0205 Phase 2b臨床解盲成功 療效顯著優於單方與安慰劑！ caliwaybiopharma.com ↗
第三方獨立盲性評估MRI數據顯示，由不同活性成分合成的CBL-514治療組別中，54.2%受試者在治療後4週，脂肪體積可減少至少20%，顯著高於安慰劑組的0%（p<0.00001），並顯著優於單一活性成分CBL-A1的17.4% (p<0.02)與CBL-A2的7.7% (p< 0.0005)，驗證CBL-514的協同療效優於個別成分。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-05 | Caliway Biopharmaceuticals Co., Ltd. | 康霈新藥最終二期CBL-514 0205 Phase 2b臨床解盲成功 療效顯著優於單方與安慰劑！ caliwaybiopharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBL-A1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005441 ↗ |